293 related articles for article (PubMed ID: 17521316)
1. Minor histocompatibility antigens as targets for immunotherapy using allogeneic immune reactions.
Akatsuka Y; Morishima Y; Kuzushima K; Kodera Y; Takahashi T
Cancer Sci; 2007 Aug; 98(8):1139-46. PubMed ID: 17521316
[TBL] [Abstract][Full Text] [Related]
2. [Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].
Hudecek M; Bartsch K; Tschiedel S; Niederwieser D
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1511-6. PubMed ID: 18597211
[TBL] [Abstract][Full Text] [Related]
3. Towards effective and safe immunotherapy after allogeneic stem cell transplantation: identification of hematopoietic-specific minor histocompatibility antigen UTA2-1.
Oostvogels R; Minnema MC; van Elk M; Spaapen RM; te Raa GD; Giovannone B; Buijs A; van Baarle D; Kater AP; Griffioen M; Spierings E; Lokhorst HM; Mutis T
Leukemia; 2013 Mar; 27(3):642-9. PubMed ID: 23079962
[TBL] [Abstract][Full Text] [Related]
4. Targeting minor histocompatibility antigens in graft versus tumor or graft versus leukemia responses.
Feng X; Hui KM; Younes HM; Brickner AG
Trends Immunol; 2008 Dec; 29(12):624-32. PubMed ID: 18952501
[TBL] [Abstract][Full Text] [Related]
5. Minor histocompatibility antigens as targets of graft-versus-leukemia reactions.
Falkenburg JH; Marijt WA; Heemskerk MH; Willemze R
Curr Opin Hematol; 2002 Nov; 9(6):497-502. PubMed ID: 12394171
[TBL] [Abstract][Full Text] [Related]
6. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation.
Spierings E; Kim YH; Hendriks M; Borst E; Sergeant R; Canossi A; Oudshoorn M; Loiseau P; Dolstra H; Markiewicz M; Leffell MS; Pereira N; Kircher B; Turpeinen H; Eliaou JF; Gervais T; Laurin D; Enczmann J; Martinetti M; Thomson J; Oguz F; Santarone S; Partanen J; Siekiera U; Alessandrino EP; Kalayoglu S; Brand R; Goulmy E
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1244-53. PubMed ID: 23756210
[TBL] [Abstract][Full Text] [Related]
7. Non-myeloablative transplants for malignant disease.
Storb RF; Champlin R; Riddell SR; Murata M; Bryant S; Warren EH
Hematology Am Soc Hematol Educ Program; 2001; ():375-91. PubMed ID: 11722994
[TBL] [Abstract][Full Text] [Related]
8. Minor histocompatibility antigens--targets of graft versus leukemia responses.
Riddell SR; Murata M; Bryant S; Warren EH
Int J Hematol; 2002 Aug; 76 Suppl 2():155-61. PubMed ID: 12430918
[TBL] [Abstract][Full Text] [Related]
9. The expanding horizon of immunotherapy in the treatment of malignant disorders: allogeneic hematopoietic stem cell transplantation and beyond.
Tsirigotis P; Shimoni A; Nagler A
Ann Med; 2014 Sep; 46(6):384-96. PubMed ID: 24888385
[TBL] [Abstract][Full Text] [Related]
10. Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.
Zilberberg J; Feinman R; Korngold R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1000-7. PubMed ID: 25459643
[TBL] [Abstract][Full Text] [Related]
11. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy.
Goulmy E
Cancer J; 2004; 10(1):1-7. PubMed ID: 15000488
[TBL] [Abstract][Full Text] [Related]
12. Separation of graft-vs.-tumor effects from graft-vs.-host disease in allogeneic hematopoietic cell transplantation.
Rezvani AR; Storb RF
J Autoimmun; 2008 May; 30(3):172-9. PubMed ID: 18242060
[TBL] [Abstract][Full Text] [Related]
13. Expanding the immunotherapeutic potential of minor histocompatibility antigens.
Spierings E; Goulmy E
J Clin Invest; 2005 Dec; 115(12):3397-400. PubMed ID: 16322786
[TBL] [Abstract][Full Text] [Related]
14. HA-1H T-Cell Receptor Gene Transfer to Redirect Virus-Specific T Cells for Treatment of Hematological Malignancies After Allogeneic Stem Cell Transplantation: A Phase 1 Clinical Study.
van Balen P; Jedema I; van Loenen MM; de Boer R; van Egmond HM; Hagedoorn RS; Hoogstaten C; Veld SAJ; Hageman L; van Liempt PAG; Zwaginga JJ; Meij P; Veelken H; Falkenburg JHF; Heemskerk MHM
Front Immunol; 2020; 11():1804. PubMed ID: 32973756
[TBL] [Abstract][Full Text] [Related]
15. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy.
Goulmy E
Immunol Rev; 1997 Jun; 157():125-40. PubMed ID: 9255626
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T-lymphocyte-defined human minor histocompatibility antigens with a restricted tissue distribution.
Warren EH; Greenberg PD; Riddell SR
Blood; 1998 Mar; 91(6):2197-207. PubMed ID: 9490709
[TBL] [Abstract][Full Text] [Related]
17. A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation.
Martin PJ; Levine DM; Storer BE; Zheng X; Jain D; Heavner B; Norris BM; Geraghty DE; Spellman SR; Sather CL; Wu F; Hansen JA
Front Immunol; 2021; 12():782152. PubMed ID: 34868058
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4 new HLA-DR-restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity.
Stumpf AN; van der Meijden ED; van Bergen CA; Willemze R; Falkenburg JH; Griffioen M
Blood; 2009 Oct; 114(17):3684-92. PubMed ID: 19706888
[TBL] [Abstract][Full Text] [Related]
20. Minor Histocompatibility Antigen-Specific T Cells.
Summers C; Sheth VS; Bleakley M
Front Pediatr; 2020; 8():284. PubMed ID: 32582592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
